Correction to: Malignant Pleural Mesothelioma

Takashi Nakano and Takashi Kijima

Correction to:
Viral Immune Therapy and Other Virotherapies
for Advanced Mesothelioma: Are We Ready for
Clinical Trials of Viral Immune Therapy?

https://doi.org/10.1007/978-981-15-9158-7_25

In chapter 25, Table 1 - Current clinical trials of virontherapy for pleural mesothelioma has been included.

The online version of this chapter can be found at https://doi.org/10.1007/978-981-15-9158-7_25

© Springer Nature Singapore Pte Ltd. 2021
T. Nakano, T. Kijima (eds.), *Malignant Pleural Mesothelioma*, Respiratory
Disease Series: Diagnostic Tools and Disease Managements,
https://doi.org/10.1007/978-981-15-9158-7_30

C1

Table 25.1 Current clinical trials of virotherapy for pleural mesothelioma

Virus	Genome	Alias	Phase	Trial condition	CT#	Results	Reference
Herpes Simplex Virus I	ds DNA	HSV1716 (replication competent) (ICP34.5 deletion to abolish neuroinulence)	I/II	Completed	NCT01721018	Twelve Patients were treated. An acceptable safety profile of intrapleural HSV1716 with evidence of viral replication and antitumor immunogenicity.	[12, 13]
		G47Δ (ICP34.5 & ICP47 deletion to maintain MHC class I expression of host cells)	I	Recruiting	UMIN000034063	To assess the safety of G47delta administered into the pleural cavity in subjects with progressive malignant pleural mesothelioma.	[14]
		AdV/HSV-tk (replication incompetent)	II	Not recruiting	NCT01997190	No tumor response, good safety profile, 2/21 patients	[6]
Adenovirus	ds DNA	AdV/hlFN-beta (replication incompetent)	I			repeated dosing safe, response by CT scan at 60 days in 2/10 patients	[6]
		AdV/hlFN-alpha2b (replication incompetent)	I/II	Completed	NCT01212367	P-I: 55/9 SD or PR at 60 days ref. #93 P-II: PR in 25%, SD in 62.5%, median Survival 13 months, 6/40 patients lived over 2 years ref. #94	[15, 16]
		AdV/hlFN-alpha2b (replication incompetent) in combination w/ Celecoxib and Gemcitabine	III	Recruiting	NCT03710876		[18]
		ONCOS-102 (Adv5/3-D24-GM-CSF) insertion of Ad3 fiber knob to Ad5-D24-GM-CSF in combination w/ Cisplatin/Pemetrexed	I/II	Not recruiting	NCT02879669	The intrapleural combined w/ chemotherapeutic agents vs chemotherapeutic agents alone. Two patients given, it w/ cyclophosphamide. One patient was recruited.	[17, 18]

		ONCOS-102 in combination w/ Durvalumab	I/II	Recruiting	NCT02963831		
Vaccinia	ds DNA	GL-ONC1	I	Not recruiting	NCT01766739	Eleven MPM patients were treated. Single dose, intrapleural administration of GL-ONC1 is safe, but is best suited for patients with MPM whose disease is limited to the pleura.	[19, 20]
Measles	ss(-) RNA	MV-NIS Edmonston strain w/ insertion of NIS gene (replication competent)	I	Not recruiting	NCT01503177 NCT01119664	The bestresponse was SD. The intrapleural administration of MV-NIS is safe, resulting in SD in 67% of patients.	[21, 22]
Inactivated Sendai virus (Non-replicating)	ss(-) RNA	GEN0101	I	Completed	UMIN000019345	Safety and tolerability of GEN0101 intratumoral adaministration for six chemotherapy-resisant MPM patients were confirmed.	[25, 26]
	ss(-) RNA	GEN0101 in combination w/ Cisplatin/Pemetrexed	II	Recruiting	JapicCTI-194617 ref. NCT 03818893		